Document type
ArticleVersion
Accepted versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/164980
Enzymatic replacement therapy for lysosomal storage disorders: Drug evaluations review in Spain
Journal Title
Authors
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
In the European Union companies only need to demonstrate that the risk-benefit balance of the new drug is favourable to obtain the authorization to sell new drugs. Hence a comparison with available treatments, a cost-effectiveness analysis and the place in the therapy of the new drug are not required. Therefore, it is necessary to carry out these analyses in an additional study. In Spain there is no national government agency, which conducts a centralized evaluation and makes decisions on funding and are the Pharmacy and Therapeutics committees that take mandatory decisions for the entire region.
Subject
Subject (English)
Citation
Collections
Citation
DARBÀ, Josep and ASCANIO, Meritxell. Enzymatic replacement therapy for lysosomal storage disorders: Drug evaluations review in Spain. Health Policy and Technology. 2019. Vol. 8, num. 1, pags. 14-23. ISSN 2211-8837. [consulted: 17 of June of 2026]. Available at: https://hdl.handle.net/2445/164980